196 related articles for article (PubMed ID: 24134151)
1. Fibroblast growth factor receptor 2: a therapeutic target in gastric cancer.
Hong L; Han Y; Liu J; Brain L
Expert Rev Gastroenterol Hepatol; 2013 Nov; 7(8):759-65. PubMed ID: 24134151
[TBL] [Abstract][Full Text] [Related]
2. Saracatinib impairs the peritoneal dissemination of diffuse-type gastric carcinoma cells resistant to Met and fibroblast growth factor receptor inhibitors.
Yamaguchi H; Takanashi M; Yoshida N; Ito Y; Kamata R; Fukami K; Yanagihara K; Sakai R
Cancer Sci; 2014 May; 105(5):528-36. PubMed ID: 24612061
[TBL] [Abstract][Full Text] [Related]
3. FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.
Kunii K; Davis L; Gorenstein J; Hatch H; Yashiro M; Di Bacco A; Elbi C; Lutterbach B
Cancer Res; 2008 Apr; 68(7):2340-8. PubMed ID: 18381441
[TBL] [Abstract][Full Text] [Related]
4. Epithelial-mesenchymal transition confers resistance to selective FGFR inhibitors in SNU-16 gastric cancer cells.
Grygielewicz P; Dymek B; Bujak A; Gunerka P; Stanczak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K; Zdzalik D
Gastric Cancer; 2016 Jan; 19(1):53-62. PubMed ID: 25407459
[TBL] [Abstract][Full Text] [Related]
5. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure.
Azuma K; Tsurutani J; Sakai K; Kaneda H; Fujisaka Y; Takeda M; Watatani M; Arao T; Satoh T; Okamoto I; Kurata T; Nishio K; Nakagawa K
Biochem Biophys Res Commun; 2011 Apr; 407(1):219-24. PubMed ID: 21377448
[TBL] [Abstract][Full Text] [Related]
6. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Takeda M; Arao T; Yokote H; Komatsu T; Yanagihara K; Sasaki H; Yamada Y; Tamura T; Fukuoka K; Kimura H; Saijo N; Nishio K
Clin Cancer Res; 2007 May; 13(10):3051-7. PubMed ID: 17505008
[TBL] [Abstract][Full Text] [Related]
7. Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer.
Chang J; Wang S; Zhang Z; Liu X; Wu Z; Geng R; Ge X; Dai C; Liu R; Zhang Q; Li W; Li J
Oncotarget; 2015 Feb; 6(4):2009-22. PubMed ID: 25576915
[TBL] [Abstract][Full Text] [Related]
8. Is FGFR2 a Suitable Target to Treat Scirrhous-Type Gastric Cancer?
Yasui W
Ann Surg Oncol; 2019 Apr; 26(4):926-927. PubMed ID: 30623340
[No Abstract] [Full Text] [Related]
9. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
10. RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance.
Salm F; Cwiek P; Ghosal A; Lucia Buccarello A; Largey F; Wotzkow C; Höland K; Styp-Rekowska B; Djonov V; Zlobec I; Bodmer N; Gross N; Westermann F; Schäfer SC; Arcaro A
Oncogene; 2013 Aug; 32(34):3944-53. PubMed ID: 23027129
[TBL] [Abstract][Full Text] [Related]
11. miR‑494 inhibits cancer‑initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2‑positive gastric cancer.
Yu Y; Yu X; Liu H; Song Q; Yang Y
Int J Mol Med; 2018 Aug; 42(2):998-1007. PubMed ID: 29786108
[TBL] [Abstract][Full Text] [Related]
12. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
13. Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors.
Wang D; Yang L; Yu W; Zhang Y
Expert Opin Investig Drugs; 2019 Oct; 28(10):903-916. PubMed ID: 31560229
[No Abstract] [Full Text] [Related]
14. Recent advances and future trends in the targeted therapy of metastatic gastric cancer.
Al-Batran SE; Werner D
Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):555-69. PubMed ID: 24665840
[TBL] [Abstract][Full Text] [Related]
15. cMET as a potential therapeutic target in gastric cancer (Review).
Teng L; Lu J
Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
[TBL] [Abstract][Full Text] [Related]
16. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
[TBL] [Abstract][Full Text] [Related]
17. New targeted therapies for gastric cancer.
Asaoka Y; Ikenoue T; Koike K
Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
[TBL] [Abstract][Full Text] [Related]
18. Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?
Hierro C; Alsina M; Sánchez M; Serra V; Rodon J; Tabernero J
Ann Oncol; 2017 Jun; 28(6):1207-1216. PubMed ID: 28327938
[TBL] [Abstract][Full Text] [Related]
19. FGF signaling network in the gastrointestinal tract (review).
Katoh M; Katoh M
Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
[TBL] [Abstract][Full Text] [Related]
20. c-Met targeting in advanced gastric cancer: An open challenge.
Marano L; Chiari R; Fabozzi A; De Vita F; Boccardi V; Roviello G; Petrioli R; Marrelli D; Roviello F; Patriti A
Cancer Lett; 2015 Aug; 365(1):30-6. PubMed ID: 26049023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
